<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559856</url>
  </required_header>
  <id_info>
    <org_study_id>COBRRA Pilot</org_study_id>
    <secondary_id>20150574-01H</secondary_id>
    <nct_id>NCT02559856</nct_id>
  </id_info>
  <brief_title>Comparison of Bleeding Risk Between Rivaroxaban and Apixaban</brief_title>
  <acronym>COBRRA Pilot</acronym>
  <official_title>Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood&#xD;
      thinners for the treatment of blood clots. Half of the patients will receive apixaban and&#xD;
      half will receive rivaroxaban. The main objective is to determine the feasibility of patient&#xD;
      recruitment and resources required to follow enrolled patients and inform for a larger,&#xD;
      multi-centered trial and to assess which one is safer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recently developed new oral anticoagulants (OAC) overcome some of the limitations of&#xD;
      established therapy with vitamin K antagonists (VKA) and low molecular weight heparin (LMWH)&#xD;
      for treatment of acute venous thromboembolism (VTE), due to ease of administration and more&#xD;
      predictable pharmacokinetic properties. Many clinical questions about the new OAC remain&#xD;
      unanswered because there have not been direct head-to-head comparison trials. For example,&#xD;
      although studies have shown that rivaroxaban and apixaban are at least as effective and safe&#xD;
      as LMWH and VKA, meta-analyses suggest that apixaban may be associated with lower bleeding&#xD;
      risk. Concerns about the potential impact of medication non-adherence have been raised.&#xD;
      Compliance with twice daily medications (e.g. apixaban) is often worse than once daily&#xD;
      medications (e.g. rivaroxaban). Both of these medications are approved by Health Canada for&#xD;
      treatment of VTE yet there is genuine uncertainty about which of the two direct OAC confer&#xD;
      the best risk-to-benefit ratio.This is a multi-centre, prospective randomized open blinded&#xD;
      end-point (PROBE) trial assessing clinical feasibility for a larger multi-centered trial&#xD;
      comparing bleeding outcomes using apixaban vs. rivaroxaban for treatment of acute VTE. The&#xD;
      primary objective of the study is to determine if it is feasible to conduct a large&#xD;
      randomized multicenter trial comparing apixaban vs. rivaroxaban for the treatment of acute&#xD;
      VTE. The secondary objectives are to assess safety and superiority of apixaban vs&#xD;
      rivaroxaban.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients screened who are eligible to participate in the trial</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of eligible patients who consent to participate in the trial</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who attend each follow-up visit</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients completing all required study procedures, per follow-up visit</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Events</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
    <description>Major bleeding events, clinically relevant non-major and minor bleeding episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Thromboembolism</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
    <description>Recurrent VTE and VTE related-death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
    <description>All-cause mortality rates&#xD;
Individual rates of death related to VTE, cardiovascular disease, bleeding or other causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance as assessed by study pill count</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-event analysis</measure>
    <time_frame>For the duration of the study 3-6 months</time_frame>
    <description>The time-to-first occurrence of secondary outcomes between randomization and end of follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 mg PO twice-a-day for 1 week, then 5 mg PO, twice daily for 3 or 6 months of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg PO twice-a-day for 3 weeks, then 20 mg PO once daily for 3 or 6 months of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed newly diagnosed acute VTE (proximal lower extremity DVT and segmental or&#xD;
             greater PE)&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication for anticoagulation such as active bleeding&#xD;
&#xD;
          -  Clinically significant liver disease or alanine aminotransferase (ALT) levels ≥ 3&#xD;
             times the upper limit of normal range&#xD;
&#xD;
          -  Creatinine clearance &lt; 30 ml/min calculated with the Cockcroft-Gault formula (29)&#xD;
&#xD;
          -  Known allergies to either apixaban or rivaroxaban&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Use of contraindicated medications with apixaban or rivaroxaban&#xD;
&#xD;
          -  Active malignancy in the last 6 months (excluding localized skin malignancy)&#xD;
&#xD;
          -  No private insurance coverage for the study drug or not willing to pay for study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lana Castellucci, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital - General Campus</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôtel-Dieu de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <last_update_submitted>October 31, 2021</last_update_submitted>
  <last_update_submitted_qc>October 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

